You may vote once every thirty days. View institutional ownership trends for Celldex Therapeutics. Since then, CLDX shares have increased by 1,150.2% and is now trading at $25.38. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. The KIT receptor tyrosine kinase is expressed in various cells, including mast cells, which mediate inflammatory responses such as hypersensitivity and allergic reactions. Celldex Therapeutics is headquartered at 53 FRONTAGE ROAD SUITE 220, HAMPTON NJ, 08827. Celldex Therapeutics (CLDX) stock price, charts, trades & the US's most popular discussion forums. Hives (urticaria) are red, itchy welts that result from a skin reaction. Benzinga does not provide investment advice. It develops CDX-1140, an agonist human monoclonal antibody, which is being studied as a single-agent and in combination with CDX-301 in a Phase I dose-escalation study in metastatic solid tumors and B cell lymphomas; CDX-3379, a monoclonal antibody designed to block the activity of ErbB3 that is in an early Phase II study in advanced head and neck squamous cell cancer in combination with Erbitux; CDX-0159, a Phase I monoclonal antibody that binds the KIT receptor and inhibits its activity; and CDX-527, a bispecific antibody that uses anti-PD-L1 and CD27 human antibodies to couple CD27 co-stimulation with blockade of the PD-L1/PD-1 pathway. See What Biden and the Democrats Just Did To YOUR Money. Please log in to your account or sign up in order to add this asset to your watchlist. Analyst Report: Baxter International Inc. Celldex Therapeutics' management team includes the following people: Shameful! Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. Top institutional investors include Acuta Capital Partners LLC (4.11%), Renaissance Technologies LLC (2.65%), BlackRock Inc. (2.18%), TSP Capital Management Group LLC (1.02%), Artal Group S.A. (1.01%) and Candriam Luxembourg S.C.A. Company insiders that have bought Celldex Therapeutics stock in the last two years include Anthony S Marucci, Diane C Young, James J Marino, Margo Heath-Chiozzi, Samuel Bates Martin, and Tibor Keler. Celldex Therapeutics' stock was trading at $2.03 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). The biopharmaceutical company can be reached via phone at 908-200-7500 or via email at [email protected]. Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. View insider buying and selling activity for Celldex Therapeutics or or view top insider-buying stocks. The P/E ratio of Celldex Therapeutics is -11.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Celldex Therapeutics, Inc. (CLDX) today announced that the Company will participate in a fireside chat at the 10th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 24, 2021 at 2:20 p.m. HAMPTON, N.J., Feb. 08, 2019 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) (“Celldex” or the “Company”) today announced that its Board of Directors has approved a one-for-fifteen reverse stock split of its common stock … as Senior Vice President and General Counsel, These 5 Small-Cap Healthcare Stocks Gained the Most in 2020, Celldex Doses First Patient in Phase 1b Study of CDX-0159 in Chronic Inducible Urticaria, Celldex Therapeutics to Present at 3rd Annual Evercore ISI HealthCONx Conference, Here's Why We're Not Too Worried About Celldex Therapeutics' (NASDAQ:CLDX) Cash Burn Situation, Celldex Presents Data from Oncology Portfolio at SITC 2020, Celldex Provides Corporate Update and Reports Third Quarter 2020 Results, Celldex Therapeutics (CLDX) Reports Q3 Loss, Tops Revenue Estimates, Celldex Initiates Early-Stage Antibody Study for Skin Disorder, Dosing underway in Celldex Therapeutics' CDX-0159 early-stage skin disorder study, Celldex Therapeutics Says First Patient Dosed In Phase 1b Study Of CDX-0159 - Quick Facts, Why Celldex Has Been A Big Winner In 2020, Celldex Therapeutics Announces Closing of $150.0 Million Public Offering of Common Stock Including Full Exercise of, view top-rated stocks among Wall Street analysts, Receive Analysts' Upgrades and Downgrades Daily. Learn more. Do Not Sell My Information. The U.S. House of Representatives voted to let the IMF circulate what could be a new elite-controlled reserve currency. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey. Do Options Traders Know Something About Celldex (CLDX) Stock We Don't? ), Celldex Therapeutics has received 352 “underperform” votes. MarketBeat just released five new trading ideas, but Celldex Therapeutics wasn't one of them. Celldex Therapeutics does not have a long track record of dividend growth. There are currently 3 buy ratings for the stock. Celldex Therapeutics employs 127 workers across the globe. QQQ 314.14. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Celldex Therapeutics's stock reverse split before market open on Monday, February 11th 2019. Based on aggregate information from My MarketBeat watchlists, some companies that other Celldex Therapeutics investors own include OPKO Health (OPK), Gilead Sciences (GILD), ACADIA Pharmaceuticals (ACAD), Corbus Pharmaceuticals (CRBP), Precigen (PGEN), Micron Technology (MU), Dynavax Technologies (DVAX), Exelixis (EXEL), bluebird bio (BLUE) and SCYNEXIS (SCYX). Learn about financial terms, types of investments, trading strategies and more. See the latest Celldex Therapeutics (CLDX) stock analysis, price, forecast, news and more. Celldex Therapeutics has received a consensus rating of Buy. Free real-time prices, trades, and chat. Celldex Therapeutics, Inc. (NASDAQ:CLDX) posted its earnings results on Thursday, November, 5th. Founder, Chief Scientific Officer & Exec. All rights reserved. Vote “Outperform” if you believe CLDX will outperform the S&P 500 over the long term. On average, they expect Celldex Therapeutics' stock price to reach $35.50 in the next twelve months. Compare Top Brokerages Here. Company insiders that own Celldex Therapeutics stock include Anthony S Marucci, Diane C Young, James J Marino, Margo Heath-Chiozzi, Richard M Wright, Samuel Bates Martin and Tibor Keler. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. Vote “Underperform” if you believe CLDX will underperform the S&P 500 over the long term. In a Phase 1a single-dose, healthy volunteer study, CDX-0159 demonstrated durable plasma tryptase reductions indicative of systemic mast cell suppression/ablation. © 2021 Verizon Media. Get short term trading ideas from the MarketBeat Idea Engine. MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. An investor that had 100 shares of Celldex Therapeutics stock prior to the reverse split would have 7 shares after the split. Get daily stock ideas top-performing Wall Street analysts. Celldex Therapeutics (NASDAQ:CLDX) had its price target upped by HC Wainwright from $16.00 to $25.00 in a report released on Monday, The Fly reports. Celldex Therapeutics has received 62.07% “outperform” votes from our community. (0.87%). This suggests a possible upside of 39.9% from the stock's current price. 80.15% of the stock of Celldex Therapeutics is held by institutions. Celldex Therapeutics had a negative trailing twelve-month return on equity of 30.93% and a negative net margin of 1,069.42%. Fundamental company data provided by Zacks Investment Research. In the past three months, Celldex Therapeutics insiders have sold more of their company's stock than they have bought. Subscribe to Premium to view Fair Value for CLDX. The biopharmaceutical company earns $-50,880,000.00 in net income (profit) each year or ($3.28) on an earnings per share basis. The 1-15 reverse split was announced on Friday, February 8th 2019. VP, Start Your Risk-Free Trial Subscription Here, Editor of top German newspaper suspended in compliance probe, Timing key in consulting deal between FirstEnergy, regulator, You Must Recognize Your Own Achievements First Before Expecting Others To, The Latest: Paris may face new lockdown as ICUs fill up, 'Big burden' for schools trying to give kids internet access, The Latest: Pakistan imposes partial lockdown in some areas, Three Mall Retailers For Your Reopening Watchlist, 3 Growth Stocks with Above Market Dividend Yields, 3 Best Stocks to Buy That You’ve Probably Never Heard Of, Ferroglobe Will Get a Big Lift From Demand For Silcon Wafers, Blue Bird Stock is a Dual Tailwinds EV and Re-Opening Play, Nautilus Stock is a Pullback Buying Opportunity Here, The Launch of Truforma Should Send Zomedica to An All-Time High, Defi Markets Pause But New Highs Are In Sight, 7 Stocks That Cathie Wood is Buying And You Should Too, 7 Internet of Things Stocks That Are a Perfect Fit to Our Connected Future, 7 Undervalued Stocks That Deserve More Attention, 7 Semiconductor Stocks Set to Gain From the Chip Shortage, 7 Great Dividend Stocks to Buy For a Comfortable Retirement, 7 Penny Stocks That Don’t Care About Robinhood, 7 Hotel Stocks Just Waiting For the Vaccine, 7 Stocks to Watch When Student Debt Forgiveness Gets Passed, 7 Healthcare Stocks Delivering Innovation in 2021, 7 Lithium Stocks That Will Power the Electric Vehicle Boom, Celldex Therapeutics Announces Fireside Chat Presentation at the H.C. Wainwright Global Life Sciences Conference, Celldex Therapeutics To Test CDX-0159 In Chronic Itchy Skin Disorder, Celldex Therapeutics to Expand Development of CDX-0159 into Prurigo Nodularis (PN), Celldex Therapeutics to Present at 10th Annual SVB Leerink Global Healthcare Conference, Announcing: Celldex Therapeutics (NASDAQ:CLDX) Stock Soared An Exciting 736% In The Last Year. Price Action: CLDX closed 1.3% higher at $28.25 on Monday. The day’s price range saw the stock hit a low of $3.2835, while the highest price level was … Oil is Dead Money: Green-Energy Stocks Are Booming. View which stocks have been most impacted by COVID-19. The brokerage currently has a buy rating on the biopharmaceutical company’s stock. Celldex Therapeutics Inc (NASDAQ: CLDX) will expand the clinical development of CDX-0159 into prurigo nodularis (PN), a chronic skin disease characterized by the development of hard, intensely itchy (pruritic) nodules on the skin. Initial data is expected at the end of the first quarter of 2021. In comparing Celldex Therapeutics, Inc. (CLDX)’s stock with other industry players reveals that stock’s current price change of +4.01% and that of +940.08% over the past 12 months is in better position with that of Bristol-Myers Squibb Company (BMY) which saw its stock … Celldex Therapeutics news and CLDX price. Celldex Therapeutics, Inc. (CLDX) announced today that the Company will participate in a fireside chat at the 3rd Annual Evercore ISI HealthCONx Conference on Wednesday, December 2 at 4:20 pm ET. CLDX … The number of shares owned by shareholders was adjusted after the market closes on Friday, February 8th 2019. CLDX has a higher number of analysts covering the stock than 11.89% of stocks in the mid market cap category. View real-time stock prices and stock quotes for a full financial overview. CLDX stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, TSP Capital Management Group LLC, Hussman Strategic Advisors Inc., and Charles Schwab Investment Management Inc.. View insider buying and selling activity for Celldex Therapeutics or view top insider-selling stocks. Celldex Therapeutics' stock was trading at $2.03 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. A webcast of the presentation will be available on the "Events & Presentations" page of the "Investors & Media" section of the Celldex … Celldex Therapeutics' mailing address is 53 FRONTAGE ROAD SUITE 220, HAMPTON NJ, 08827. CDX-0159 is a humanized monoclonal antibody that binds the KIT receptor with high specificity and potently inhibits its activity. MarketBeat's community ratings are surveys of what our community members think about Celldex Therapeutics and other stocks. Cronos Stock … Their forecasts range from $35.00 to $36.00. See more from BenzingaClick here for options trades from BenzingaRevance Therapeutics' DaxibotulinumtoxinA For Injection Improves Muscle Tone In Mid-Stage Upper Limb SpasticityCompugen To Test COM701, Opdivo Combination In Solid Tumor Settings© 2021 Benzinga.com. To see all exchange delays and terms of use please see disclaimer. DOW 30,932.37. The consensus among Wall Street equities research analysts is that investors should "buy" Celldex Therapeutics stock. Shares of CLDX can be purchased through any online brokerage account. Celldex Therapeutics does not currently pay a dividend. Celldex Therapeutics trades on the NASDAQ under the ticker symbol "CLDX.". CLDX | Complete Celldex Therapeutics Inc. stock news by MarketWatch. View all of CLDX's competitors. About Us Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. The CLDX … Only 2.40% of the stock of Celldex Therapeutics is held by insiders. Currency in USD, Trade prices are not sourced from all markets. Celldex Therapeutics, Inc. (NASDAQ:CLDX)’s traded shares stood at 516,171 during the last session, with the company’s beta value hitting 3.06. Earnings for Celldex Therapeutics are expected to grow in the coming year, from ($1.81) to ($1.46) per share. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. You can opt out at any time. ET. Celldex Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, March 25th 2021. When you find (and hold) a... Investors need to pay close attention to Celldex (CLDX) stock based on the movements in the options market lately. The official website for Celldex Therapeutics is www.celldex.com. Learn more. GlobeNewsWire - 1 year ago Celldex … Celldex Therapeutics, Inc. (NASDAQ:CLDX)’s beta value is holding at 2.68, while the average true range (ATR) indicator is currently reading 1.5. How can you protect your money and all you’ve worked for from this reset? Celldex Appoints Freddy A. Jimenez, Esq. CLDX Stock Summary With a one year PEG ratio of 954.15, Celldex Therapeutics Inc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings … MarketBeat does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. Sign-up to receive the latest news and ratings for CLDX and its competitors with MarketBeat's FREE daily newsletter. View which stocks are hot on social media with MarketBeat's trending stocks report. High institutional ownership can be a signal of strong market trust in this company. The biopharmaceutical company reported ($0.36) EPS for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.36).